By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


SEARCH JOBS



Key Statistics


Email: info@adamaspharma.com
Ownership: Public

Web Site: Adamas Pharma
Employees:
Symbol: ADMS
 



Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Adamas Pharma (ADMS) To Present New ADS-5102 Data From Phase II Trial In Walking Impairment Associated With Multiple Sclerosis At ACTRIMS Forum 2017 2/17/2017 8:56:09 AM
Adamas Pharma (ADMS) Outlines Key 2017 Priorities And Highlights 2016 Achievements 1/9/2017 7:25:21 AM
Adamas Pharma (ADMS) Announces U.S. FDA Acceptance Of ADS-5102 New Drug Application For The Treatment Of Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease 1/6/2017 7:59:15 AM
Adamas Pharma (ADMS) Completes Phase I Clinical Trial Of ADS-4101 For Treatment Of Partial Onset Seizures In Patients With Epilepsy 1/4/2017 8:44:42 AM
Adamas Pharma (ADMS) Reports Third Quarter 2016 Financial Results 11/4/2016 10:51:59 AM
Adamas Pharma (ADMS) Reports Third Quarter 2016 Financial Results 11/4/2016 10:31:20 AM
Adamas Pharma (ADMS) Submits New Drug Application To U.S. FDA For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Patients With Parkinson’s Disease 10/27/2016 7:34:07 AM
Adamas Pharma (ADMS) Appoints Michael F. Bigham To Board Of Directors 9/23/2016 8:01:33 AM
Allergan (AGN) And Adamas Pharma (ADMS) Announce U.S. Availability Of New Dosage Strengths For NAMZARIC (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease 9/22/2016 8:31:03 AM
Adamas Pharma (ADMS) Announces Results Of EASE LID 3, A Pivotal Trial Of ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson’s Disease Patients At The 4th World Parkinson Congress 9/21/2016 10:48:14 AM
12345678
//-->